Drug Trial Radar · NCT06899217
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Jan 29, 2025
Primary completion
May 7, 2026
Study completion May 7, 2026
Sponsor
- Lead sponsor
- CinDome Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo * To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo Participants will go through the following schedule: * Pre-screening (1 visit) * Screening \& Lead-In (1-2 visits) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation. * Lead-In Period (1 visit) * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * 15 mg CIN-102, taken orally BID for 12 weeks * 10 mg CIN-102, taken orally BID for 12 weeks * Placebo for CIN-102, taken orally BID for 12 weeks
Conditions
- Idiopathic Gastroparesis
Interventions
CIN-102 Dose 15mgDrug
Twice daily for 12 weeks
PlaceboDrug
Twice daily for 12 weeks
CIN-102 Dose 10mgDrug
Twice daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.Time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline
Locations
85 sites in 1 country. Site status is shown where the registry gives one.
Gastro Health - Birmingham
Birmingham, Alabama
G & L Research, LLC
Foley, Alabama
The Center for Clinical Trials
Saraland, Alabama
Del Sol Research Management, LLC
Tucson, Arizona
Applied Research Center of Arkansas, Inc
Little Rock, Arkansas
Preferred Research Partners, Inc.
Little Rock, Arkansas
Hope Clinical Research LLC
Canoga Park, California
Erick H. Alayo Medical Corporation
Chula Vista, California
Flourish Research - Los Angeles (Covina)
Covina, California
Gastro Care Institute
Lancaster, California
Downtown L.A. Research Center, Inc.
Los Angeles, California
Acclaim Clinical Research
San Diego, California
Focus Clinical Research - West Hills
West Hills, California
University of Colorado Anschutz
Aurora, Colorado
Rocky Mountain Gastroenterology (RMG)
Lakewood, Colorado
Paradigm Research - Wheatridge
Wheat Ridge, Colorado
Connecticut Clinical Research Institute, LLC
Bristol, Connecticut
American Family Research Group
Cape Coral, Florida
USA and International Research Inc.
Doral, Florida
Unique Clinical Trials
Doral, Florida
Advanced Medical Research Group
Hollywood, Florida
Nature Coast Clinical Research
Inverness, Florida
ENCORE Borland Groover Clinical Research
Jacksonville, Florida
Allied Biomedical Research Institute, Inc.
Miami, Florida
Advanced Research Institute Inc
New Port Richey, Florida
Sensible Healthcare, LLC
Ocoee, Florida
GCP Research
St. Petersburg, Florida
Summit Clinical Research, LLC
Athens, Georgia
DelRicht Clinical Research - Atlanta
Atlanta, Georgia
Gastrointestinal Specialists of Georgia PC
Marietta, Georgia
Treasure Valley Medical Research
Boise, Idaho
GI Alliance - Gurnee
Gurnee, Illinois
Carle Clinic - Urbana Main
Urbana, Illinois
Integrated Clinical Trial Services, Inc
West Des Moines, Iowa
Kansas Medical Clinic, P.A.
Topeka, Kansas
University of Louisville
Louisville, Kentucky
Tandem Clinical Research
Marrero, Louisiana
Delta Research Partners of West Monroe, LLC
Monroe, Louisiana
NOLA Research Works
New Orleans, Louisiana
Portland Gastroenterology Associates
Portland, Maine
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.